Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial (Q42950968)

11 November 2017

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial (English)

1 reference

11 November 2017

1 reference

H K Genant

1

1 reference

11 November 2017

C G Peterfy

2

1 reference

11 November 2017

R Westhovens

3

1 reference

11 November 2017

J-C Becker

4

1 reference

11 November 2017

R Aranda

5

1 reference

11 November 2017

G Vratsanos

6

1 reference

11 November 2017

J Teng

7

1 reference

11 November 2017

J M Kremer

8

1 reference

11 November 2017

language of work or name

English

0 references

publication date

17 December 2007

1 reference

Annals of the Rheumatic Diseases

11 November 2017

1 reference

11 November 2017

67

1 reference

11 November 2017

8

1 reference

11 November 2017

1084-1089

1 reference

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

11 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

T-cell regulation in rheumatoid arthritis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Cytokine pathways and joint inflammation in rheumatoid arthritis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

The links between joint damage and disability in rheumatoid arthritis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Smallest detectable difference in radiological progression.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569144

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

3 November 2018

1 reference

12 December 2020

Methods of assessing radiographic change in rheumatoid arthritis

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2007.085084

1 reference

11 November 2017

1 reference

11 November 2017

PubMed publication ID

18086727

1 reference